ResMed shareholders also sleep well at night

August 6, 2018

Sleep device maker ResMed this morning reported a 13% increase in revenue for the year ended 30 June 2018 together with a 27% increase in operating income. Chief Executive, Mick Farrell, was reported as saying that “we closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth, driven by geographically balanced results across our entire portfolio of offerings”.  The company is well positioned for fiscal year 2019.

Resmed is one of Morgan Wealth’s core shareholdings and has produced a return of 47% for the 12 months ended 31 July 2018.

Our Top Stock Picks
Total returns on capital growth and dividends for 12 months ended 31 December 2019. Past performance is not a reliable indicator of future performance.
Zip Co Ltd
224.77%
Afterpay Touch
136.13%
Nanosonics
123.59%
Appen Limited
75.68%
Nearmap Ltd
69.33%
CSL Limited
50.37%
ResMed Inc
38.53%
Rio Tinto Limited
33.94%
Macquarie Group
32.49%
Atlas Arteria
31.84%
ASX200 Accum Index (comparison)
23.40%